Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

August 4-5, 2017

Philadelphia, PA

JAK Inhibitors in Myeloproliferative Neoplasms–Improving Patient Outcomes through Precision Therapy

A Luncheon Symposium at US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes


Saturday, August 27, 2016

12:20 pm – 2:20 pm
Edison Ballroom ABC, The Westin Alexandria
Alexandria, Virginia

Chair
Ruben A. Mesa, MD

Mayo Clinic College of Medicine
Phoenix, Arizona

Continuing Education

ACCMEImedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend
This live activity is specifically designed to meet the educational needs of hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) who are involved and/or interested in the treatment of patients with targetable MPN.

Objectives
Upon successful completion of this educational activity, participants should be better able to:

  • Evaluate finalized and ongoing clinical trial data utilizing JAK inhibitors for the treatment of patients with MPN
  • Identify appropriate patient populations for JAK inhibitor therapy in MPN
  • Define drug- and disease-related adverse events in the use of JAK inhibitors for MPN
  • Formulate optimal evidence-based strategies that balance efficacy, adverse events, and quality of life for patients with MPN on or considering JAK inhibitor therapy

Faculty

Ruben A. Mesa, MD
Mayo Clinic College of Medicine
Phoenix, Arizona

Stephen T. Oh, MD, PhD
Washington University School of Medicine
St. Louis, Missouri

Srdan Verstovsek, MD, PhD
MD Anderson Cancer Center
The University of Texas
Houston, Texas

Agenda

12:20 pm

Lunch

12:40 pm

Welcome and pre-activity polling via ARRAY

12:50 pm

Lecture: Is there a role for JAK inhibitors in Essential Thrombocythemia (ET)?
Stephen T. Oh, MD, PhD

1:10 pm

Case study: Inadequately controlled Polycythemia Vera (PV)
Srdan Verstovsek, MD, PhD

1:30 pm

Lecture: Treatment option for Cytopenic Myelofibrosis (MF)
Ruben A. Mesa, MD

1:50 pm

Panel discussion: Recap of key points, and post-activity polling via ARRAY
All faculty

2:00 pm

Adjourn

Support

The following company has provided an educational grant in support of this symposium:

Incyte Corporation

Registration

The JAK Inhibitors in Myeloproliferative Neoplasms–Improving Patient Outcomes through Precision Therapy symposium will be presented at the US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes meeting and is open to attendees registered for that meeting.

To register for US Focus on MPN/MDS please follow this link: http://imedex.com/us-myeloproliferative-neoplasms-myelodysplastic-syndromes/registration.asp. There is no additional fee to attend the symposium and pre-registration for the symposium is not required.